High plasma levels of islet amyloid polypeptide in young with new-onset of type 1 diabetes mellitus.

• Main Authors: Johan F Paulsson, Johnny Ludvigsson, Annelie Carlsson, Rosaura Casas, Gun Forsander, Sten A Ivarsson, Ingrid Kockum, Åke Lernmark, Claude Marcus, Bengt Lindblad, Gunilla T Westermark
• Format: Article
• Language: English
• Published: Public Library of Science (PLoS) 2014-01-01
• Series: PLoS ONE
• Online Access: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24671002/pdf/?tool=EBI
• ISSN: 1932-6203

<h4>Aims/hypothesis</h4>Islet amyloid polypeptide (IAPP) is a beta cell hormone secreted together with insulin upon glucose stimulation. IAPP participates in normal glucose regulation, but IAPP is also known for its ability to misfold and form islet amyloid. Amyloid fibrils form through smaller cell toxic intermediates and deposited amyloid disrupts normal islet architecture. Even though IAPP and amyloid formation are much discussed in type 2 diabetes, our aim was to study the significance of IAPP in type 1 diabetes.<h4>Results</h4>Plasma IAPP levels in children and adolescents with newly diagnosed type 1 diabetes (n = 224) were analysed and concentrations exceeding 100 pmol/L (127.2-888.7 pmol/L) were found in 11% (25/224). The IAPP increase did not correlate with C-peptide levels.<h4>Conclusions/interpretation</h4>Plasma levels of IAPP and insulin deviate in a subpopulation of young with newly-diagnosed type 1 diabetes. The determined elevated levels of IAPP might increase the risk for IAPP misfolding and formation of cell toxic amyloid in beta cells. This finding add IAPP-aggregation to the list over putative pathological factors causing type 1 diabetes.